Earning Analysis
Welcome to our in-depth analysis of VolitionRX Ltd(VNRX) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of VolitionRX Ltd earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
| FY2024Q4 | 2025-03-31 | After Hours | -0.06 | -0.06 | - | 545.34K | 191.66K | -64.85 | -9.03 | -6.63 |
| - | 2024-08-15 | Pre-Market | -0.09 | - | - | 340.00K | - | - | +3.64 | +23.64 |
| FY2024Q1 | 2024-05-13 | - | -0.11 | -0.10 | +9.09 | 389.52K | 171.54K | -55.96 | +6.02 | -7.23 |
| FY2023Q4 | 2024-03-25 | - | - | -0.11 | - | 505.60K | 243.97K | -51.75 | -1.37 | +5.48 |
| FY2023Q3 | 2023-11-14 | - | -0.12 | -0.11 | +8.33 | 346.60K | 165.21K | -52.33 | -7.23 | -12.05 |
| FY2023Q2 | 2023-08-14 | - | -0.13 | -0.14 | -7.69 | 271.25K | 216.31K | -20.25 | - | +5.69 |
| - | 2023-03-15 | - | -0.15 | -0.13 | +13.33 | - | - | - | -15.38 | -7.14 |
| - | 2022-11-14 | - | -0.15 | -0.14 | +6.67 | - | - | - | -2.92 | +12.87 |
| - | 2022-08-10 | - | -0.15 | -0.14 | +6.67 | - | - | - | +0.50 | -1.99 |
| - | 2022-05-11 | - | 0.04 | -0.14 | -450.00 | - | - | - | -5.26 | +9.31 |
VNRX Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, VolitionRX Ltd reported performance for FY2024Q4, announced on 2025-03-31. The company achieved an EPS of -0.06, compared to analyst estimates of -0.06 by 0.00% . Revenue for the quarter reached 191.66K compared to expectations of 545.34K by -64.85% .
The stock price reacted with a -9.03% one-day change and a -6.63% five-day change following the earnings release. These movements reflect market reaction in VolitionRX Ltd growth trajectory and strategic initiatives.
VNRX Earnings Forecast
Looking ahead, VolitionRX Ltd(VNRX) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q4 project quarter revenue of 990.58K and an EPS of -0.04.
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been Revise Downward by -13.19%, while EPS estimates have been Revise Upward by 11.73%. For the upcoming Q4 2025, revenue estimates have been adjusted Revise Downward by -26.09% . These revisions correlate with a -48.27% change in stock price over the same period, suggesting potential buying opportunities for investors who believe in VolitionRX Ltd long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between VNRX's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
Revise Downward
-13.19%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+11.73%
In Past 3 Month
Revenue Estimates for Q4 2025
Revise Downward
-26.09%
In Past 3 Month
Stock Price
Go Down
-48.27%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:1.99M
--
EPS Estimate-Annual FY 2025:-0.21
—
Stock Price0.31
VNRX Revenue and EPS Performance: A Historical Perspective
VolitionRX Ltd revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2024Q4 (2025-03-31,After Hours):
EPS: -0.06 (Actual) vs.-0.06 (Estimate) (0.00%)
Revenue: 191.66K (Actual) vs. 545.34K (Estimate) (-64.85%)
Price Reaction: -9.03%(1-Day), -6.63%(5-Day)
(2024-08-15,Pre-Market):
EPS: (Actual) vs.-0.09 (Estimate) (%)
Revenue: 0.00 (Actual) vs. 340.00K (Estimate) (%)
Price Reaction: 3.64%(1-Day), 23.64%(5-Day)
FY2024Q1 (2024-05-13,):
EPS: -0.10 (Actual) vs.-0.11 (Estimate) (9.09%)
Revenue: 171.54K (Actual) vs. 389.52K (Estimate) (-55.96%)
Price Reaction: 6.02%(1-Day), -7.23%(5-Day)
Earnings Reaction
The chart below shows how VNRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, VNRX sees a +13.30% change in stock price 10 days leading up to the earnings, and a +1.76% change 10 days following the report. On the earnings day itself, the stock moves by -1.84%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in DEC/2024, the stock changed -9.03% on the day following the earnings release and then changed by -11.91% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
VolitionRX Ltd (VNRX) Q3 2025 Earnings Call Summary
Neutral
2025-11-14
The earnings call reveals mixed signals: strong cost management and significant partnership potential, but unpredictable revenues and no revenue guidance for 2025. The Q&A highlights optimism about partnerships and market expansion, but also notes unclear timelines and revenue breakdowns. These factors suggest limited immediate impact on stock price, leading to a neutral prediction.
VolitionRX Ltd (VNRX) Q2 2025 Earnings Call Summary
Positive
2025-08-15
Despite lacking a market cap, the company shows significant potential with a 44% revenue growth, improved net loss, and ongoing licensing discussions. The Q&A highlights strong interest in the Nu.Q platform, repeat orders, and potential revenue from the Taiwan program. However, the absence of revenue guidance and confidentiality on human deals add uncertainty. Overall, the positive aspects, especially the strong revenue growth and potential new deals, outweigh the negatives, suggesting a positive stock price movement.
VolitionRX Ltd (VNRX) Q1 2025 Earnings Call Summary
Neutral
2025-05-20
The earnings call presents mixed signals. While there are positive aspects like revenue growth, cost management, and milestone payments, the absence of revenue guidance and declining cash position raise concerns. The Q&A section reveals uncertainty in revenue predictability and challenges in maintaining cost levels. Overall, the lack of specific guidance and potential financial risks balance out the positives, suggesting a neutral sentiment towards the stock price movement.
VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Summary
Neutral
2025-04-02
The earnings call presents mixed signals: strong revenue growth and reduced expenses are positive, but lack of 2025 guidance and regulatory uncertainties are concerns. The Q&A reveals cautious optimism about new projects and milestone payments, but management's unclear responses on some topics raise doubts. Overall, the absence of clear guidance and competitive pressures balance out the positive financial metrics, leading to a neutral sentiment.
VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Summary
Neutral
2025-03-31
The earnings call presents mixed indicators. Financial performance shows growth with 59% revenue increase, but cash usage is high. Product updates are positive, but regulatory and competitive risks loom. Q&A reveals optimism about future payments and studies, but management's lack of clarity on key projects raises concerns. The absence of market cap data and strategic plan limits insight, leading to a neutral sentiment.
VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Summary
Neutral
2025-03-31
The earnings call reflects a mixed sentiment. Positive factors include significant revenue growth and reduced operating expenses, but concerns arise from high cash burn and regulatory uncertainties. The Q&A revealed management's optimism about future milestones and automation, yet lacked clarity on certain operational details. Overall, the financial performance and optimistic guidance balance out the risks and uncertainties, leading to a neutral stock price prediction.
VolitionRx Limited (VNRX) Q3 2024 Earnings Call Summary
Positive
2024-11-15
The earnings call summary indicates strong revenue growth, significant cost reductions, and a clear path towards cash neutrality by 2025. The Q&A section provides additional insights, such as a strong market presence in Japan and expected operational expense reductions. Although there are competitive pressures and funding risks, the company's positive financial metrics and optimistic future outlook suggest a positive stock price movement over the next two weeks.
People Also Watch
FAQ
What were the key highlights of VNRX’s latest earnings report for FY2024Q4?
How did VNRX’s stock price react after the FY2024Q4 earnings release?
What are the revenue and EPS estimates for VNRX for 2025/Q4?
How does VNRX’s stock price correlate with earnings forecast revisions?
What should investors expect from VNRX’s next earnings report?